{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:20:02Z","timestamp":1794406802661,"version":"4.9.0"},"reference-count":52,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T00:00:00Z","timestamp":1628035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>The rates of refractory pediatric psoriasis and atopic dermatitis (AD) have steadily risen over the last few decades, demanding newer and more effective therapies. This review aims to explore the reasons for resistant disease, as well as its management; this includes the indications for, efficacy of, and safety of current therapies for refractory pediatric dermatologic disease. A PubMed search for key phrases was performed. Poor medication adherence is the most common cause of resistant disease and may be managed with techniques such as simplified treatment regimens, more follow-ups and educational workshops, as well as framing and tailoring. Once problems with adherence are ruled out, escalating treatment to stronger biologic therapy may be indicated. Development of anti-drug antibodies (ADAs) can cause patients\u2019 disease to be refractory in the presence of potent biologics, which may be addressed with regular medication use or concomitant methotrexate. If patients with AD fail to respond to biologic therapy, a biopsy to rule out mycosis fungoides, or patch testing to rule out allergic contact dermatitis, may be indicated. A limitation of this study is the absence of more techniques for the management of poor medication adherence. Managing medication adherence, escalating treatment when appropriate, and addressing possible anti-drug antibodies will help assure control and relief for patients with resistant disease.<\/jats:p>","DOI":"10.3390\/biomedicines9080958","type":"journal-article","created":{"date-parts":[[2021,8,4]],"date-time":"2021-08-04T08:47:52Z","timestamp":1628066872000},"page":"958","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Refractory Pediatric Psoriasis and Atopic Dermatitis: The Importance of Therapeutical Adherence and Biological Management"],"prefix":"10.3390","volume":"9","author":[{"given":"Katherine A.","family":"Kelly","sequence":"first","affiliation":[{"name":"Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC 27103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adaora","family":"Ewulu","sequence":"additional","affiliation":[{"name":"Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC 27103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica K.","family":"Emmerich","sequence":"additional","affiliation":[{"name":"Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC 27103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney E.","family":"Heron","sequence":"additional","affiliation":[{"name":"Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC 27103, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0090-6289","authenticated-orcid":false,"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC 27103, USA"},{"name":"Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC 27103, USA"},{"name":"Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC 27103, USA"},{"name":"Department of Dermatology, University of Southern Denmark, 5230 Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,4]]},"reference":[{"key":"ref_1","first-page":"28","article-title":"New and emerging topical therapies for psoriasis and atopic dermatitis","volume":"12","author":"Psomadakis","year":"2019","journal-title":"J. Clin. Aesthet. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/ajd.12331","article-title":"Factors contributing to poor treatment outcomes in childhood atopic dermatitis","volume":"56","author":"Sokolova","year":"2015","journal-title":"Australas. J. Dermatol."},{"key":"ref_3","first-page":"278","article-title":"Diagnosis and management of psoriasis","volume":"63","author":"Kim","year":"2017","journal-title":"Can. Fam. Phys."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1177\/1203475418818082","article-title":"Psoriasis and Atopic Dermatitis \u201cResistant\u201d to Topical Treatment Responds Rapidly to Topical Desoximetasone Spray","volume":"23","author":"Hogue","year":"2019","journal-title":"J. Cutan. Med. Surg."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e13185","DOI":"10.1111\/dth.13185","article-title":"A novel vehicle for the treatment of psoriasis","volume":"33","author":"Dattola","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1001\/jamadermatol.2014.5254","article-title":"Frequency of primary nonadherence to acne treatment","volume":"151","author":"Anderson","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jaad.2008.03.045","article-title":"One in 3 prescriptions are never redeemed: Primary nonadherence in an outpatient clinic","volume":"59","author":"Storm","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S235","DOI":"10.1016\/j.jaad.2005.10.060","article-title":"Adherence with topical treatment is poor compared with adherence with oral agents: Implications for effective clinical use of topical agents","volume":"54","author":"McCarty","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1111\/bjd.15085","article-title":"Long-term adherence to topical psoriasis treatment can be abysmal: A 1-year randomized intervention study using objective electronic adherence monitoring","volume":"176","author":"Alinia","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"499","DOI":"10.5021\/ad.2015.27.5.499","article-title":"Topical corticosteroid phobia among parents of children with atopic eczema in Korea","volume":"27","author":"Lee","year":"2015","journal-title":"Ann. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.2147\/PPA.S167508","article-title":"Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: A systematic literature review","volume":"12","author":"Murage","year":"2018","journal-title":"Patient Prefer. Adherence"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"West, C., Narahari, S., O\u2019Neill, J., Davis, S., Huynh, M., Clark, A., Boles, A., and Feldman, S.R. (2013). Adherence to adalimumab in patients with moderate to severe psoriasis. Dermatol. Online J., 19.","DOI":"10.5070\/D3195018182"},{"key":"ref_13","unstructured":"(2021, July 23). Why Price of Humira Keeps Rising Despite FDA Approval of Generic Competition\u2014The Washington Post. Available online: https:\/\/www.washingtonpost.com\/business\/economy\/why-humiras-price-keeps-rising-despite-fda-approval-of-generic-competition\/2020\/01\/07\/549ed0ce-2e3a-11ea-bcb3-ac6482c4a92f_story.html."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1080\/09546630802032611","article-title":"\u201cCoral reef\u201d psoriasis: A marker of resistance to topical treatment","volume":"19","author":"Feldman","year":"2008","journal-title":"J. Dermatol. Treat."},{"key":"ref_15","first-page":"205","article-title":"Topical corticosteroids for treatment-resistant atopic dermatitis","volume":"102","author":"Okwundu","year":"2018","journal-title":"Cutis"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/09546634.2019.1617830","article-title":"Is topical treatment effective for psoriasis in patients who failed topical treatment?","volume":"32","author":"Okwundu","year":"2021","journal-title":"J. Dermatol. Treat."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s40257-017-0261-5","article-title":"Increasing Adherence with Topical Agents for Atopic Dermatitis","volume":"18","author":"Patel","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3390\/jcm4020231","article-title":"Interventions to Increase Treatment Adherence in Pediatric Atopic Dermatitis: A Systematic Review","volume":"4","author":"Bass","year":"2015","journal-title":"J. Clin. Med."},{"key":"ref_19","first-page":"833","article-title":"Underuse of early follow-up visits: A missed opportunity to improve patients\u2019 adherence","volume":"13","author":"Davis","year":"2014","journal-title":"J. Drugs Dermatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1001\/archdermatol.2010.368","article-title":"A randomized controlled pilot study of the effects of an extra office visit on adherence and outcomes in atopic dermatitis","volume":"146","author":"Sagransky","year":"2010","journal-title":"Arch. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/pde.13991","article-title":"Does it work and is it safe? Parents\u2019 perspectives on adherence to medication for atopic dermatitis","volume":"37","author":"Capozza","year":"2020","journal-title":"Pediatr. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Adler-Neal, A.L., Cline, A., Frantz, T., Strowd, L., Feldman, S.R., and Taylor, S. (2019). Complementary and Integrative Therapies for Childhood Atopic Dermatitis. Children, 6.","DOI":"10.3390\/children6110121"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1001\/jamadermatol.2019.0106","article-title":"Using Complementary and Alternative Medicine for the Treatment of Psoriasis: A Step in the Right Direction","volume":"155","author":"Nwabudike","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1001\/jamadermatol.2014.2274","article-title":"Comparative prevalence of complementary and alternative medicine use among outpatients in dermatology and primary care clinics","volume":"150","author":"Sivamani","year":"2014","journal-title":"JAMA Dermatol."},{"key":"ref_25","first-page":"216","article-title":"Alternative therapies commonly used within a population of patients with psoriasis","volume":"58","author":"Fleischer","year":"1996","journal-title":"Cutis"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.jaad.2020.01.044","article-title":"Placebo tailoring improves patient satisfaction of treatment plans in atopic dermatitis","volume":"83","author":"Bashyam","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1080\/09546634.2018.1530442","article-title":"Caregiver willingness to treat atopic dermatitis is not much improved by anchoring","volume":"30","author":"Curry","year":"2019","journal-title":"J. Dermatol. Treat."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.jaad.2020.03.074","article-title":"Framing atopic dermatitis topical medication application site discomfort as a signal of efficacy improves willingness to continue use","volume":"83","author":"Bashyam","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/jamadermatol.2019.4029","article-title":"Comparison of Biologics and Oral Treatments for Plaque Psoriasis: A Meta-analysis","volume":"156","author":"Armstrong","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/17512433.2018.1449642","article-title":"Dupilumab for treatment of atopic dermatitis","volume":"11","author":"Srour","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1016\/j.jaad.2020.06.054","article-title":"Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial","volume":"83","author":"Paller","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_32","first-page":"93","article-title":"Drug focus: Adalimumab in the treatment of moderate to severe psoriasis","volume":"1","author":"Vena","year":"2007","journal-title":"Biol. Targets Ther."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/bjd.18029","article-title":"Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study","volume":"181","author":"Papp","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa066886","article-title":"Etanercept Treatment for Children and Adolescents with Plaque Psoriasis","volume":"358","author":"Paller","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/BTT.S252578","article-title":"Biologic treatments of psoriasis: An update for the clinician","volume":"15","author":"Brownstone","year":"2021","journal-title":"Biol. Targets Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/jdv.16124","article-title":"Long-term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease","volume":"34","author":"Reich","year":"2020","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/jdv.17002","article-title":"Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial","volume":"35","author":"Bodemer","year":"2021","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/bjd.19147","article-title":"Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS)","volume":"183","author":"Paller","year":"2020","journal-title":"Br. J. Dermatol."},{"key":"ref_39","unstructured":"(2021, July 23). Psoriatic Arthritis Biologic Medication|Taltz\u00ae (Ixekizumab). Available online: https:\/\/www.taltz.com\/psoriatic-arthritis?utm_source=google&utm_medium=ppc&campaign=2062306002&adgroup=81830157968&ad=498825047518&utm_keyword=kwd-393065621989&gclid=Cj0KCQjw9O6HBhCrARIsADx5qCQF0y9CUhc0Npiclh05QLl0lgrmemWOt0mWHgs2_H7PDljAhCngM6waAkc-EALw_wcB."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2147\/PHMT.S75836","article-title":"Efficacy and safety of ustekinumab in adolescents","volume":"7","author":"Kellen","year":"2016","journal-title":"Pediatr. Health Med. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jaad.2015.07.002","article-title":"Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study","volume":"73","author":"Landells","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40265-017-0693-5","article-title":"Incidence, Prevention and Management of Anti-Drug Antibodies against Therapeutic Antibodies in Inflammatory Bowel Disease: A Practical Overview","volume":"77","author":"Hindryckx","year":"2017","journal-title":"Drugs"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1093\/rheumatology\/kev356","article-title":"Biologic efficacy optimization\u2014A step towards personalized medicine","volume":"55","author":"Kiely","year":"2016","journal-title":"Rheumatology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar3147","article-title":"The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: A review","volume":"12","author":"Krieckaert","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1136\/ard.2006.065615","article-title":"Clinical response to adalimumab: Relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis","volume":"66","author":"Bartelds","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.2006.099978","article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn\u2019s disease","volume":"56","author":"Vermeire","year":"2007","journal-title":"Gut"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1586\/1744666X.2013.836060","article-title":"Anti-drug antibodies in psoriasis: A critical evaluation of clinical significance and impact on treatment response","volume":"9","author":"Hsu","year":"2013","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e234445","DOI":"10.1136\/bcr-2020-234445","article-title":"Severe adult-onset atopic dermatitis mistaken for cutaneous T-cell lymphoma in a medically complex patient","volume":"13","author":"Hinkamp","year":"2020","journal-title":"BMJ Case Rep."},{"key":"ref_49","unstructured":"(2021, July 23). Two Cases of Mycosis Fungoides Diagnosed after Treatment Non-Response to Dupilumab. Available online: https:\/\/pubmed-ncbi-nlm-nih-gov.go.libproxy.wakehealth.edu\/33560800\/."},{"key":"ref_50","first-page":"296","article-title":"Contact Dermatitis, Patch Testing, and Allergen Avoidance","volume":"112","author":"Burkemper","year":"2015","journal-title":"Mo. Medi."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.jaad.2008.08.028","article-title":"Psoriasis: Improving adherence to topical therapy","volume":"59","author":"Feldman","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Amoruso, G.F., Nistic\u00f2, S.P., Iannone, L., Russo, E., Rago, G., Patruno, C., and Bennardo, L. (2021). Ixekizumab may improve renal function in psoriasis. Healthcare, 9.","DOI":"10.3390\/healthcare9050543"}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/8\/958\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:40:22Z","timestamp":1760164822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/9\/8\/958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,4]]},"references-count":52,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8]]}},"alternative-id":["biomedicines9080958"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines9080958","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,4]]}}}